Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates Cytochalasin Z11 reduces osteoclastogenesis by attenuating c-Fos and NF-κB signaling, suggesting therapeutic potential for osteoclast-related diseases.
. Furthermore, CytoZ11 was demonstrated to suppress NFATc1 activation, which is due to the attenuation of two signaling pathways: c-Fos signaling and the NF-κB pathway. In summary, this study revealed that CytoZ11 may become a prospective drug for osteoclast-related disease by inhibiting osteoclast formation and function.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: